

Alopecia Treatment Pipeline Review H1 2016

Global Alopecia Drugs and Companies Pipeline Review H1 2016

PUNE, INDIA, August 30, 2016

/EINPresswire.com/ -- Summary

'[Alopecia](#) - Pipeline Review, H2 2016', provides an overview of the Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.



Complete report details @ <https://www.wiseguyreports.com/reports/619287-alopecia-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ <https://www.wiseguyreports.com/sample-request/619287-alopecia-pipeline-review-h2-2016>

Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia
- The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects
- The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alopecia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alopecia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ <https://www.wiseguyreports.com/enquiry/619287-alopecia-pipeline-review-h2-2016>

Key points in table of content

Table of Contents 2

List of Tables 5

List of Figures	6
Introduction	7
Global Markets Direct Report Coverage	7
Alopecia Overview	8
Therapeutics Development	9
Pipeline Products for Alopecia - Overview	9
Pipeline Products for Alopecia - Comparative Analysis	10
Alopecia - Therapeutics under Development by Companies	11
Alopecia - Therapeutics under Investigation by Universities/Institutes	13
Alopecia - Pipeline Products Glance	14
Late Stage Products	14
Clinical Stage Products	15
Early Stage Products	16
Alopecia - Products under Development by Companies	17
Alopecia - Products under Investigation by Universities/Institutes	20
Alopecia - Companies Involved in Therapeutics Development	21
Ache Laboratorios Farmaceuticos S/A	21
Aclaris Therapeutics, Inc.	22
Allergan Plc	23
Almirall, S.A.	24
AndroScience Corporation	25
Berg LLC	26
BiologicsMD, Inc.	27
Bristol-Myers Squibb Company	28
Concert Pharmaceuticals, Inc.	29
Diffusion Pharmaceuticals Inc.	30
Follicum AB	31
Handok Inc.	32
Histogen, Inc.	33
Hyundai Pharmaceutical Co., Ltd.	34
Incyte Corporation	35
Kuhnle Pharmaceutical Co., Ltd.	36
Lee's Pharmaceutical Holdings Limited	37
LEO Pharma A/S	38
NovaLead Pharma Pvt. Ltd.	39
Novartis AG	40
Panacea Biotec Limited	41
Quark Pharmaceuticals, Inc.	42
RepliCel Life Sciences, Inc.	43
RXi Pharmaceuticals Corporation	44
Sucampo Pharmaceuticals, Inc.	45
SWITCH Biotech LLC	46
Taisho Pharmaceutical Holdings Co., Ltd.	47

TetraLogic Pharmaceuticals 48
Tigo GmbH 49
Valeant Pharmaceuticals International, Inc. 50
Vida Therapeutics Inc. 51
Alopecia - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 56
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
abatacept - Drug Profile 63
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 68
Antisense Oligonucleotide to Antagonize Androgen Receptor for Alopecia - Drug Profile 69
ASCJ-9 - Drug Profile 70
ATI-50001 - Drug Profile 72
ATI-50002 - Drug Profile 73
bimatoprost - Drug Profile 74
BMD-1141 - Drug Profile 76
BMD-1341 - Drug Profile 77
BMD-2341 - Drug Profile 78
BQ-A - Drug Profile 79
BRM-421 - Drug Profile 80
calcitriol - Drug Profile 81
CB-0301 - Drug Profile 82
CTP-543 - Drug Profile 84
DHL-HisZnNa - Drug Profile 85
diphencyprone - Drug Profile 86
finasteride - Drug Profile 88
finasteride - Drug Profile 89
FOL-005 - Drug Profile 90
FS-2 - Drug Profile 93
Hair Stimulating Complex - Drug Profile 94
HL-5945 - Drug Profile 96
HTB-005 - Drug Profile 97
interferon beta-1b - Drug Profile 98
KI-1104 - Drug Profile 99
KI-1105 - Drug Profile 100
LEO-124249 - Drug Profile 101
minoxidil - Drug Profile 102

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-

[USD&report_id=619287](#)

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/342361567>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.